logo
How to limit the spread of COVID, cold and flu at home in winter

How to limit the spread of COVID, cold and flu at home in winter

Winter can be a contagious time of year for everything from COVID-19 to the common cold.
Once someone in your household feels the first ominous tickle at the back of their throat, everyone else can feel doomed to follow.
"It's always a challenge within households because we know households are the place where viruses like respiratory viruses spread really efficiently," says Catherine Bennett, Deakin University's chair of epidemiology.
But there are ways to limit the risk of illnesses spreading from one family member or housemate to another, she says.
Professor Bennett says if someone within your household becomes sick, it is possible you have already been exposed before they had any symptoms.
However, if the sick person can isolate from the rest of household it's still worth it, she says. Ideally this would look like using a separate bedroom and bathroom to others.
She says this degree of isolation is not possible or realistic for many households.
Isolation can also look like someone sleeping on the couch to "reduce their risk of inhaling the virus" from their unwell partner overnight, she says.
Medical director for government-funded online public health information service Healthdirect Darran Foo says if possible, the symptomatic person should remain isolated from the rest of the household until they no longer have active symptoms.
For example, "no more ongoing fevers, no more coughing up lots of phlegm".
If someone in the household is symptomatic, and isolating completely is not possible, Professor Bennett says a mask can help protect the rest of the household.
"Wearing a mask if you're unwell can reduce your risk of passing it on to other people."
Dr Foo also advises wearing a mask if it's possible and practical, particularly if you live in a smaller home like an apartment.
Dr Foo recommends throwing used tissues away immediately and avoiding sharing cups, plates and cutlery in the household when someone is unwell, whether from a cold or COVID-19.
"The biggest thing really is to maintain good hygiene, especially good hand hygiene," Dr Foo says.
"Lots of hand washing and using sanitisers as much as possible."
Professor Benett also says you should "wash your own hands more often in between touching things, even around the home" when you or someone else is sick.
She recommends wiping down commonly used surfaces — such as the bathroom — more often. Any surfaces where someone has coughed may have droplets over them, she says.
Professor Bennett says "bugs do so well [in winter because] we can't air our houses out".
Poor ventilation will make it easier for viruses to spread, but she says increasing air turnover and introducing outdoor air can help.
Open doors and windows when you can "so it's not the same air pushing right through the household that's around the person who's unwell."
Dr Foo also says the more ventilation you can get at home the better, while of course avoiding hypothermia.
Dr Foo says "the general advice all remains the same" if someone in the household is potentially more vulnerable.
However, he says people more at risk of becoming seriously unwell may want to consult their regular healthcare professional who knows their medical history.
"It really depends on that person's risk, their comorbidities and what ongoing conditions they have — and also to identify whether it's appropriate to use antiviral medication at that point in time."
Professor Bennett says being diligent with mask wearing, hand washing and sanitising surfaces is particularly worth doing if someone in the house is vulnerable.
Professor Bennett says being up to date with COVID-19 and influenza vaccinations will offer another layer of protection.
"If you can't avoid infection in the household — and that's the hardest place to do it — then actually having some protection from severe illness is really important in influenza."
In larger shared households there are more people to bring viruses home and that extra protection from vaccination is even more important, "particularly from severe illness in the vulnerable people in our households", Professor Bennett says.
Dr Foo also encourages people to stay up to date with their vaccinations, "especially their annual flu vaccination and their COVID booster shots".
This is general information only. For personal advice, you should see a qualified medical practitioner.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Australians with family stuck in Iran are living a nightmare. Trauma stalks those who escaped
Australians with family stuck in Iran are living a nightmare. Trauma stalks those who escaped

ABC News

timean hour ago

  • ABC News

Australians with family stuck in Iran are living a nightmare. Trauma stalks those who escaped

Azar has not slept properly in days. In May, her 70-year-old mother Frances went to Iran to see her sisters — her first visit to the country in roughly a decade. Frances is now one of around 3,000 Australians and their families registered with the Department of Foreign Affairs and Trade (DFAT) for assistance to leave — almost two weeks after Israeli bombs started falling on the capital Tehran. On the advice of DFAT, Frances made the perilous overland journey to the Iran-Azerbaijan border hoping to cross. Instead, Azerbaijan officials said she needed a visa and a special code — and knocked her back. DFAT has said some staff from its Iran embassy have remained at the Azerbaijan border to help Australians. But Azar said they were unable to assist her mother. "We didn't ask for buses, we didn't ask for planes … just open that damn door when they get there," she said. "Have someone to verify their identification with their passports. That isn't difficult to do." Early in the morning on Thursday (Sydney time), DFAT finally sent a code to Azar and Frances that would have allowed the mother to cross into Azerbaijan. But Frances, who ran out of medication for her heart condition while waiting for days at the Azerbaijan border, was forced to travel further back into Iran to seek urgent medical help. "She is the best hands-on grandma you could imagine. She does everything with my kids and for my kids," Azar said. The ABC understands that Foreign Minister Penny Wong has raised concerns with the speed of processing of border crossing codes with her Azerbaijani counterpart. As with other people in this story, the ABC is not publishing Azar and Frances's full names due to ongoing safety concerns. Iran and Israel have agreed to a shaky ceasefire, but being in Iran remains dangerous. Iran's Health Minister Mohammad Reza Zafarghandi this week said more than 600 people had died in Israeli strikes during the war. The US-based Human Rights Activists group, based on figures collated from Iranian sources, put the death toll higher at 1,054. Just days after Israel began bombing Iran in mid-June, DFAT evacuated its staff from Tehran to Azerbaijan. "The government has a responsibility to ensure the safety of our staff," Senator Wong said at the time. "We do not have to cast our minds back too far in history to understand the risk to foreign officials in Iran in times of unrest." Melbourne woman Mehi, who managed to escape Iran last week into Turkiye without DFAT assistance, said she felt abandoned by the Australian government. The evacuation of the embassy showed DFAT knew how to move Australians out of Iran, Mehi said. "How come no-one sent me an email to say … 'there's a transport for all the Iranian-Australians, you can catch this bus?'" she said. "You know the way to help other citizens. Why didn't you help us? "You could have just had two buses there, take them to the border with Turkiye or Armenia, and help them to escape." Unlike neighbouring Azerbaijan, Armenia does not require Australians to hold a visa for entry. DFAT responded to the ABC's inquiries but did not address many of the specific concerns raised. "DFAT officers in Azerbaijan, including at its border crossing, are working hard to support Australians seeking to leave Iran," a spokesperson said in a statement. "DFAT is working with Azerbaijan authorities to help facilitate border crossing codes. "We acknowledge that the number of people seeking to leave as well as the unstable internet connectivity in Iran is making the border crossing more difficult. "Unfortunately, at this stage our ability to provide consular services is extremely limited due to the situation on the ground." Adelaide woman Naz Forooz, who first spoke to the ABC's Radio National Breakfast this week, found herself in a similar situation to Azar. Ms Forooz's mother — who was in Iran to farewell her own dying mother — also travelled to the border on the advice of DFAT and was turned back by Azerbaijan officials. Without the DFAT advice to go to the Azerbaijan border crossing people would have instead gone to the borders with Turkiye or Armenia, Ms Forooz said. "But because [DFAT] said that there was help available, people started flooding [to the Azerbaijan border crossing] and then the system just couldn't handle it." Azar agreed, arguing that people would not have gone to the Azerbaijan border had DFAT not directed them to do so. "It looks like the ones that followed the DFAT advice were the most vulnerable ones ... like elderly women travelling on their own," she said. "Armenia and Turkiye were the obvious choices. Or they would just stay put." The US has encouraged Americans in Iran to exit via land borders into Azerbaijan, Armenia or Turkiye "if they can do so safely". Chinese state media reported this week that its embassy had managed to get almost all Chinese nationals out of Iran, after booking 17 buses to evacuate people via land border crossings into Turkmenistan and Azerbaijan. India's Ministry of Foreign Affairs said it has evacuated some 2,576 Indians from Iran since last week. Mehi decided "no-one is going to do anything for us" and left Tehran one day before Israeli strikes hit the offices of Iran's state broadcaster — next door to Mehi's family home. She said DFAT's communications had been generic and unhelpful — urging her to follow Smartraveller on social media for updates. But Iranian authorities have regularly cut off internet access in the country since the war with Israel broke out — at times for days at a time. "Are you serious? I just asked for help, you're asking me to look at Instagram and Facebook," Mehi said. "I'm dealing with my life and my family." Ms Forooz's mother is, for now, still in Iran. Ms Forooz told the ABC she was left with "zero faith" in DFAT and frustration at a perceived lack of urgency by the department. "It feels like I have done a lot more to organise her path back home than DFAT has," she said. "There's obviously been a systematic failure. There's been a complete lack of clear communication and the information they've given us turned out to be wrong. Safe in Melbourne, Mehi worries for her Iranian family members who can't leave the country. The trauma of their harrowing escape into Turkiye, during which Mehi held onto pepper spray because she feared what people might do to them along the way, meant she has been unable to return to work. Her 22-year-old daughter, a science student at Deakin University, had not left the house since arriving into Melbourne last Thursday. "We pay our taxes ... we are just the same as other communities," Mehi said. "The most painful part is no-one helped us." Other Iranian-Australians who spoke to the ABC resoundingly felt the response was drastically different to that for Australian citizens in Israel. Several government-assisted flights this week have helped hundreds of Australians flee Tel Aviv. Flight tracking website Flightradar24 reported on Thursday morning (Sydney time) that Iranian airspace over Tehran and western parts of the country remained closed. Azar said her mother Frances — a NSW nurse for several decades — had been let down by what she saw as a government that "doesn't care about [Iranians] as a community". "She's dedicated most of her life to serving the Australian community," Azar said. "Is it that one person born in one country, has priority over someone born in another? "Because that's what it looks like."

Doctors at Westmead Hospital to hold vote of no confidence in health district chief executive, amid delayed cancer scans
Doctors at Westmead Hospital to hold vote of no confidence in health district chief executive, amid delayed cancer scans

ABC News

time4 hours ago

  • ABC News

Doctors at Westmead Hospital to hold vote of no confidence in health district chief executive, amid delayed cancer scans

Doctors at Sydney's Westmead Hospital are calling for their chief executive to stand down over allegations of patient safety concerns and delayed cancer diagnoses. In a letter sent to hospital staff, the Medical Staff Council said it plans to hold a vote of no confidence in Western Sydney Local Health District's chief executive, Graeme Loy, on Thursday evening. Senior doctors say for the past five years they have raised concerns about unacceptable clinic wait times for routine scans that can detect preventable cancers, with some patients waiting up to three years. "You will be aware that the [Medical Staff Council] has advocated for many years for improvement in patient care including excessive delays in clinic review, procedures and surgical admissions," deputy chair of the Westmead Medical Staff Council Jenny King wrote in the letter. "This has been a particular concern for those patients with a positive faecal occult blood screen. "The issue of failure to provide care for those patients at high-risk malignancy has long been documented," Dr King wrote. Western Sydney Local Health District, Health Minister Ryan Park and NSW Health have been contacted for comment. The revolt among staff came after the dismissal of Westmead's head of gastroenterology department, Jacob George, last week, who raised concerns with management about the lengthy wait times. One senior doctor at Westmead, who spoke on the condition of anonymity, believed Professor George's dismissal was retaliation for speaking out. "For many years we have been struggling to have our concerns listened to, and the executive has been aware," the doctor said. The ABC understands wait times have impacted cancer diagnosis screenings in several departments including cardio, renal, dermatology and gastroenterology. The senior doctor said the delays could mean hundreds of patients who have cancer are in the dark about their disease, or receive late diagnoses. "It's a major risk and it's something we shouldn't be letting people down on," the doctor said. "If you have a possible cancer, we like to get a colonoscopy done within 30 days, but patients are waiting months, and the risk is the cancer has disseminated." Kathryn Austin, Australian Medical Association NSW president, said the issues were symptomatic of a lack of investment in staffing in public hospitals. "There has not been the investment in workforce that we need and the workforce is who deliver the care to patients," she said. "It's a sad state of affairs that it's come to this point and the clinical concerns haven't been addressed." A vote of no confidence has no binding power and does not mean Mr Loy will be dismissed from this role if passed. But the senior doctor said the significance of an unanimous vote would be hard to ignore. "If we don't win, the whole of public health is threatened," the senior doctor said.

Health Check: Paradigm makes scenic acquisitive detour, but it's no strategic shift
Health Check: Paradigm makes scenic acquisitive detour, but it's no strategic shift

News.com.au

time6 hours ago

  • News.com.au

Health Check: Paradigm makes scenic acquisitive detour, but it's no strategic shift

Paradigm Biopharmaceuticals will spend up to $16.5 million on an oral drug asset, but stays focused on its phase III knee trial Percheron enters headline $450 million cancer drug acquisition Neurizon goes from solid to liquid with its motor neurone disease drug candidate Paradigm Biopharmaceuticals (ASX:PAR) is taking the acquisitive scenic route in its quest to develop an effective knee osteoarthritis treatment, but says it remains focused on its phase III knee trial. In a heavily back-ended deal, Paradigm will pay as much as $16.5 million to purchase Proteobioactives Pty Ltd. This company owns an early-stage oral candidate for minor to mild osteoarthritis (OA), called Pentacoxib. The proposed drug combines pentosan polysulfate sodium (PPS) – Paradigm's core asset – with a COX-2 inhibitor (Coxib). The idea is to improve drug 'bioavailability': a shortcoming of many oral drugs. The deal expands Paradigm's remit into the OA-related pain market, such as hand OA, mild knee OA and the veterinary market (dogs and horses). Proof of concept data shows meaningful pain reduction in patients with hand and knee OA. 'Strategic alignment' Paradigm touts Pentacoxib as an alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), which are 'not known to improve structures of the arthritic joint'. Paradigm dubs the purchase as a 'strategic alignment' with its core program, which is about developing its repurposed PPS (Zilosul) for moderate to severe knee OA. The acquired asset moves the company down the OA 'severity spectrum' and maintains Paradigm's focus on a non-opioid alternative. Proteobioactives was founded by Professor Peter Ghosh, who pioneered PPS research. The deal gives Paradigm exclusive global rights to develop and commercialise the PPS-Coxib combo for pain and inflammation. The acquisition enables 'potential expansion into earlier-stage disease segments where large unmet needs remain.' Now to the financial nitty gritty: The deal involves an upfront $500,000 in cash and a $1 million milestone payment on completion of a phase II trial. Paradigm pays a further $5 million on 'successful completion' of a phase III trial. A further $5 million is paid on US Food & Drug Administration approval. There's more! Another $5 million is due on the sale of an FDA registered product, 'as evidenced by the submission of a sales invoice, proof of delivery, or other relevant documentation". Keep your receipts guys! The deal is modest bet for Paradigm relative to its long-awaited phase III knee OA. The study in underway across up to 15 Australian and 50 US sites. Percheron finds a new purpose Having scoured for a new asset following the failure of its flagship clinical program, Percheron Therapeutics (ASX:PER) has settled on a Singapore-based cancer drug candidate. This is by way of an exclusive license agreement with Hummingbird Bioscience, for a monoclonal antibody therapy with potential applications in several cancers. Percheron hopes to start a clinical trial of the candidate, dubbed HMBD-002, next year. Percheron will pay Hummingbird an upfront US$ 3 million ($4.6 million), with contingent milestone payments of up to US$287 million ($443 million), plus royalties to boot. Naturally, the big bucks are later in the piece. Taking in the VISTA HMBD-002 targets a bodily agent called VISTA, as in 'v-domain immunoglobulin suppressor of T-cell activation'. But we knew that already. A novel target, 'VISTA potentially represents a new mechanism to treat a diverse range of tumours.' HMBD-002 has passed a phase I trial in the US, which showed the agent to be 'pharmacologically active" and generally safe and well-tolerated. 'After the challenges of recent months, we are once again a mid-clinical stage drug development business,' says Percheron CEO Dr James Garner. The 'challenges' refer to two board spills – both unsuccessful – after the company's Duchenne muscular dystrophy trial proved an unmitigated flop. Percheron shares this morning rebounded as much as 30%, or one-third of a cent. Neurizon eyes easier drug delivery While Paradigm goes from liquid to solid, Neurizon Therapeutics (ASX:NUZ) is moving the other way with its drug candidate to treat amyotrophic lateral sclerosis (ALS, a form of motor neurone disease). The liquid formulation of Neurizon's candidate NUZ-001 is designed to support patients with all stages of ALS, 'particularly those with swallowing difficulties such as bulbar onset'. The first manifestation of ALS, bulbar onset can lead to difficulties with speech (dysarthria), swallowing (dysphagia), and sometimes breathing. Neurizon will integrate the liquid form into its ongoing NUZ-001 program, starting with a human bioequivalence study in the first half of 2026. The company says the formulation resulted from direct feedback from patients and carers. 'As ALS progresses, patients face increasing challenges with day-to-day activities, including something as fundamental as swallowing,' Neurizon chief Dr Michael Thurn says. Rainforest foraging leads to cancer drug hope The private, eternal IPO candidate Qbiotics has reported 'highly encouraging' results from a phase II study of its cancer therapy sourced from the Daintree rainforest. The trial targets soft tissue sarcoma, a rare cancer that generally forms as a painless lump (tumour) in any one of the soft tissues in the body. Qbiotics' candidate, tigilanol tiglate activates a certain protein to stimulate the immune system and destroy tumours. In stage one of the trial, ten evaluable patients achieved an objective response rate of 80%, 'based on the best observed response". In other words, eight out of ten evaluable patients saw either complete ablation or partial ablation (more than 30% reduction in volume) of treated tumours. Also, 22 of the 27 injected tumours across all patients showed complete or partial ablation (14 showing complete ablation). None of the 14 completely ablated tumours recurred at 6 months, "indicating tigilanol tiglate may provide durable responses". 'Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging," Qbiotics chief Stephen Doyle says. Now moving to expanded stage two, the trial is being carried out at New York's Memorial Sloan Kettering Cancer Center. Eureka! moment Qbiotics founder Dr Gordon and her forest ecologist husband Dr Paul Reddell stumbled on the therapeutic benefits of tigilanol tiglate while fossicking in rainforest in the Atherton Tablelands of Far North Queensland. They observed that animals spat out the seed of the blushwood tree, pointing to a nontoxic deterrent preventing the critters from eating and thus destroying the seed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store